摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

Methyl 2,3-O-Isopropylidene-β-D-ribo-pentodialdo-1,4-furanoside | 611184-75-9

中文名称
——
中文别名
——
英文名称
Methyl 2,3-O-Isopropylidene-β-D-ribo-pentodialdo-1,4-furanoside
英文别名
(3aR,4S,6S,6aR)-4-methoxy-2,2-dimethyl-3a,4,6,6a-tetrahydrofuro[3,4-d][1,3]dioxole-6-carbaldehyde
Methyl 2,3-O-Isopropylidene-β-D-ribo-pentodialdo-1,4-furanoside化学式
CAS
611184-75-9
化学式
C9H14O5
mdl
——
分子量
202.207
InChiKey
UEMZYXSQHWVRNA-XUTVFYLZSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

物化性质

  • 沸点:
    275.9±40.0 °C(Predicted)
  • 密度:
    1.22±0.1 g/cm3(Predicted)

计算性质

  • 辛醇/水分配系数(LogP):
    0.08
  • 重原子数:
    14.0
  • 可旋转键数:
    2.0
  • 环数:
    2.0
  • sp3杂化的碳原子比例:
    0.89
  • 拓扑面积:
    53.99
  • 氢给体数:
    0.0
  • 氢受体数:
    5.0

上下游信息

  • 下游产品
    中文名称 英文名称 CAS号 化学式 分子量

反应信息

点击查看最新优质反应信息

文献信息

  • Substituted pyrrolo[2,3-d]pyrimidines as inhibitors of protein arginine methyl transferase 5 (PRMT5)
    申请人:PRELUDE THERAPEUTICS, INCORPORATED
    公开号:US11524962B2
    公开(公告)日:2022-12-13
    The disclosure is directed to compounds of Formula (I) and Formula (II). Formula (I) and Formula (II) and pharmaceutically acceptable salts or solvates thereof. Pharmaceutical compositions comprising compounds of Formula (I) or Formula (II), as well as methods of their use and preparation, are also described.
    本公开涉及式(I)和式(II)化合物。式(I)和式(II)及其药学上可接受的盐或溶液。还描述了包含式(I)或式(II)化合物的药物组合物及其使用和制备方法。
  • A general method for the synthesis of 1,1-difluoroalkylphosphonates
    作者:Stephen F. Martin、Daniel W. Dean、Allan S. Wagman
    DOI:10.1016/s0040-4039(00)74156-6
    日期:1992.3
    A facile method for preparing 1,1-difluoroalkylphosphonates has been developed that features radical deoxygenation of thionocarbonates derived from the adducts formed upon addition of 9 to aldehydes.
  • TROST, B. M.;BONK, P. J., J. AMER. CHEM. SOC., 1985, 107, N 6, 1778-1781
    作者:TROST, B. M.、BONK, P. J.
    DOI:——
    日期:——
  • SELECTIVE INHIBITORS OF PROTEIN ARGININE METHYLTRANSFERASE 5 (PRMT5)
    申请人:PRELUDE THERAPEUTICS, INCORPORATED
    公开号:US20210403472A1
    公开(公告)日:2021-12-30
    The disclosure is directed to compounds of Formula (I) and Formula (II). Formula (I) and Formula (II) and pharmaceutically acceptable salts or solvates thereof. Pharmaceutical compositions comprising compounds of Formula (I) or Formula (II), as well as methods of their use and preparation, are also described.
查看更多